910 Clopper Road
United States - Map
GenVec, Inc., a clinical-stage biopharmaceutical company, focuses on using its adenovector gene delivery platform to develop a pipeline of therapeutics and vaccines in the United States. Its vaccine against foot and mouth disease in cattle has been approved. The companys lead product candidate, CGF166 is in Phase 1/2 clinical study for the treatment of hearing loss and balance disorders. Its product pipeline also includes GV2311, a vaccine for respiratory syncytial virus; and GV2207, a herpes simplex virus-2 immunotherapeutic. The company is also developing vaccines against other infectious diseases, such as Enterovirus D68 (EV-D68) and malaria. GenVec, Inc. has partnership agreements with Novartis AG, Laboratory of Malaria Immunology and Vaccinology, Washington University, and Merial Limited, as well as with TheraBiologics, Inc. to develop cancer therapeutics. The company was founded in 1992 and is based in Gaithersburg, Maryland.
|Mr. Douglas J. Swirsky CPA, CFA,
Chief Exec. Officer, Pres, Corp. Sec. and Director
|Dr. Douglas E. Brough Ph.D.,
Chief Scientific Officer
|Dr. Bryan T. Butman Ph.D.,
Sr. VP of Devel.
|Dr. Zola P. Horovitz Ph.D.,
|Mr. James Vincent Lambert ,
Sr. Director of Accounting & Fin., Treasurer and Corp. Controller
|Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|